Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 15/20 | 0.60 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.60 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9964274 | 1.00 | STING1 (0.60) | STING1PDE3BPDE3A | |
| SCHEMBL22983981 | 1.00 | STING1 (0.60) | STING1PDE3BPDE3A | |
| SCHEMBL20149811 | 1.00 | STING1 (0.60) | STING1PDE3BPDE3A | |
| SCHEMBL14946363 | 1.00 | STING1 (0.60) | STING1PDE3BPDE3A | |
| SCHEMBL25504648 | 1.00 | STING1 (0.60) | STING1PDE3BPDE3A | |
| SCHEMBL9945531 | 0.91 | STING1 (0.49) | STING1PDE3BPDE3A | |
| SCHEMBL14946328 | 0.90 | STING1 (0.51) | STING1PDE3BPDE3A | |
| SCHEMBL26780958 | 0.87 | STING1 (0.47) | STING1PDE3BPDE3A | |
| SCHEMBL14946312 | 0.87 | STING1 (0.47) | STING1PDE3BPDE3A | |
| SCHEMBL17860546 | 0.87 | STING1 (0.58) | STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230383287-A1 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | HELIX NANOTECHNOLOGIES INC | 2023-11-30 | — | — | US | disclosed |
| US-20230383287-A1 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | HELIX NANOTECHNOLOGIES INC | 2023-11-30 | — | — | US | disclosed |
| US-11542505-B1 | Substituted RIG-I agonists: compositions and methods thereof | MERCK SHARP & DOHME LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-11267844-B2 | Spirothietane nucleosides | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-08 | — | — | US | disclosed |
| EP-3676276-B1 | SPIROTHIETANE NUCLEOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-08 | — | — | EP | disclosed |
| US-20210139524-A1 | SPIROTHIETANE NUCLEOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-13 | — | — | US | disclosed |
| US-20210095284-A1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | Janssen Biopharma, Inc. | 2021-04-01 | — | — | US | disclosed |
| US-10793859-B2 | Modified oligonucleotides and methods of use | Janssen Biopharma, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793859-B2 | Modified oligonucleotides and methods of use | NSUN2, ADAR, POLM | STING1 179/4885PDE3B 4110/4885PDE3A 4088/4885 |
| US-20230383287-A1 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | NSUN2, NSUN3, ADAR | STING1 2084/4885PDE3B 4134/4885PDE3A 3847/4885 |
| US-11267844-B2 | Spirothietane nucleosides | SAMHD1, SLC28A1, SLC28A2 | STING1 2029/4885PDE3B 482/4885PDE3A 347/4885 |
| US-20210095284-A1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | MAPT, PSEN2, NSUN2 | STING1 1409/4885PDE3B 4119/4885PDE3A 3432/4885 |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | NSUN2, ADAR, POLM | STING1 179/4885PDE3B 4110/4885PDE3A 4088/4885 |
| US-11542505-B1 | Substituted RIG-I agonists: compositions and methods thereof | MAVS, TLR3, DDX18 | STING1 7/4885PDE3B 4295/4885PDE3A 4238/4885 |
| US-20210139524-A1 | SPIROTHIETANE NUCLEOSIDES | SAMHD1, SLC28A1, SLC28A2 | STING1 2029/4885PDE3B 482/4885PDE3A 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.